99 Results

People

  1. Wang
    Wang
  2. Riviere
    Riviere
  3. Sadelain
    Sadelain
  4. Brentjens
    Brentjens
  5. Park
    Park
  6. Senechal
    Senechal
  7. Curran
    Curran
  8. Bernal
    Bernal
  9. Purdon
    Purdon
  10. Halton
    Halton

Groups

  1. Center for Hematologic Malignancies (99)
  2. Department of Medicine (99)
  3. Hematologic Malignancies Research (99)
  4. Hematologic Malignancies, Division of (99)
  5. GSK Faculty (98)
  6. Sloan Kettering Institute Faculty (90)
  7. Molecular Pharmacology and Chemistry Program Faculty (89)
  8. Adult Leukemia (75)
  9. Pediatrics, Department of (38)
  10. Stem Cell Transplantation and Cellular Therapy Service (35)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Xiuyan Wang"
Formats
  1. Meeting Abstract (70)
  2. Journal Article (27)
  3. Conference Paper (1)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (99)
  2. Department of Medicine (99)
  3. Hematologic Malignancies Research (99)
  4. Hematologic Malignancies, Division of (99)
  5. GSK Faculty (98)
  6. Sloan Kettering Institute Faculty (90)

More Groups

People
  1. Xiuyan Wang (99)
  2. Isabelle Riviere (96)
  3. Michel Sadelain (89)
  4. Renier Brentjens (65)
  5. Jae Park (64)
  6. Brigitte Senechal (35)

More People

Years
  1. 2023 (6)
  2. 2022 (7)
  3. 2021 (6)
  4. 2020 (4)
  5. 2019 (12)
  6. 2018 (8)

More Years

Publications
  1. Blood (30)
  2. Molecular Therapy (15)
  3. Journal of Clinical Oncology (13)
  4. Haematologica (5)
  5. Cancer Research (3)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Nature Publishing Group (22)
  3. American Society of Clinical Oncology (13)
  4. American Association for Cancer Research (6)
  5. Ferrata Storti Foundation (5)
  6. American Association for the Advancement of Science (3)

More Publishers

Results (99)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Disease burden and transplant on long-term survival after CD19 CAR T cells in adults with relapsed acute lymphoblastic leukemia
    Meeting Abstract

    Park, J.; Rivere, I.; Wang, X. Y.; Senechal, B.; Curran, K.; Sauter, C.; Wang, Y. Z.; Li, D.; Brentjens, R.; Sadelain, M.
    Molecular Therapy (2017)

    Fulltext@MSK | Save
  • Selection and purification of CD34+ cells from cryopreserved cord blood units using CliniMACS Plus and CliniMACS Prodigy
    Meeting Abstract

    Wang, X. Y.; Stefanski, J.; Hack, A.; He, Q.; Boyle, R.; Barker, J.; Scandura, J.; Rafii, S.; Sadelain, M.; Riviere, I.
    Molecular Therapy (2017)

    Fulltext@MSK | Save
  • Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M.; Park, J.; Rivière, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Impact of disease burden on long-term outcome of CD19-targeted CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Sadelain, M.; Brentjens, R.
    Haematologica (2016)

    Fulltext@MSK | Save
  • Evaluation of Miltenyi ExpAct and TransAct CD3/28 beads for CAR-T cell manufacturing
    Meeting Abstract

    Wang, X.; Qu, J.; Stefanski, J.; Borquez-Ojeda, O.; Hack, A.; He, Q.; Wasielewska, T.; Du, F.; Sadelain, M.; Rivière, I.
    Molecular Therapy (2016)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T cells for cancer immunotherapy
    Meeting Abstract

    Curran, K. J.; Silverman, L. B.; Kobos, R.; Kernan, N. A.; Margossian, S. P.; Park, J. H.; Sauter, C. S.; Szenes, V.; Wang, X. Y.; O'Reilly, R. J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save